Article
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
The hematology journal : the official journal of the European Haematology Association - 1 Jan 2003
Barjesteh van Waalwijk van Doorn-Khosrovani Sahar, Erpelinck Claudia, Meijer Joost, van Oosterhoud Susanna, van Putten Wim L J, Valk Peter J M, Berna Beverloo H, Tenen Daniel G, Löwenberg Bob, Delwel Ruud
Abstract excerpt
The CCAAT/enhancer binding protein alpha is an essential transcription factor for granulocytic differentiation. Recent studies reported N- and C-terminal CEBPA mutations in approximately 7% of acute myeloid leukaemia (AML) patients. C-terminal mutations are usually in-frame and occur in the basic-leucine zipper (bZIP) domain, resulting in deficient DNA binding. Using a rapid PCR approach, we screened for bZIP...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.